<DOC>
	<DOCNO>NCT03106155</DOCNO>
	<brief_summary>[ Study Design ] This study single arm , multi-center phase II study vistusertib monotherapy patient relapse small cell lung cancer ( SCLC ) harbor RICTOR amplification . Patients receive vistusertib monotherapy ( 50 mg BID per o every 12 hour ) demonstrate objective disease progression meet discontinuation criterion . [ Primary Objective ] To investigate efficacy vistusertib monotherapy patient relapse SCLC patient harbor RICTOR amplification 2nd 3rd line therapy</brief_summary>
	<brief_title>Vistusertib ( AZD2014 ) Monotherapy Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>[ Inclusion Criteria ] Provision inform consent prior study specific procedure Men woman age least 18 year Small cell lung cancer harbor RICTOR amplification Patients willing able comply protocol duration study include undergoing treatment schedule visit examination . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 deterioration previous 2 week Minimum life expectancy 12 week Patients must acceptable bone marrow , liver renal function measure within 14 day prior administration study treatment define : At least one measurable lesion accurately assess image physical examination baseline follow visit . No history nonautologous bone marrow transplant . Participation another clinical study investigational product last 21 day . Prior chemotherapy , biological therapy , radiation therapy , androgen , thalidomide , immunotherapy , anticancer agent within 21 day start study treatment . Prior use investigational monoclonal antibody therapy within 3 month . Major surgery within 4 week prior study entry ( exclude placement vascular access ) , minor surgery ( exclude tumour biopsy ) within 14 day first dose study treatment . Exposure strong moderate inhibitor inducer CYP3A4/5 , Pgp ( MDR1 ) BCRP take within state washout period first dose study treatment ( see Appendix 1 ) Exposure specific substrates drug transporter OATP1B1 , OATP1B3 , MATE1 MATE2K within appropriate washout period Any haemopoietic growth factor within 14 day prior receive study treatment . Pretreatment PI3K , AKT , dual PI3K/mTRO mTOR inhibitor Spinal cord compression and/or brain metastasis unless asymptomatic treat stable steroid least 4 week prior start study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>